Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Sean P. Bohen
|
| gptkbp:clinicalTrialPhase |
OP-1250 Phase 1/2
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
oral therapies for hormone receptor-positive breast cancer
|
| gptkbp:focusesOn |
breast cancer therapies
|
| gptkbp:foundedYear |
2007
|
| gptkbp:headquartersLocation |
gptkb:San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Olema Oncology
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:leadProductCandidate |
OP-1250
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
OLMA
|
| gptkbp:website |
https://www.olema.com/
|
| gptkbp:bfsParent |
gptkb:Boxer_Capital
|
| gptkbp:bfsLayer |
8
|